CombinatoRx reports positive Phase II for antidiabetic combo
This article was originally published in Scrip
Executive Summary
CombinatoRx says that its type 2 diabetes drug, CRx-401, has met its primary endpoint in Phase II trials. Preliminary results show that CRx-401 performed significantly better than bezafibrate alone on the reduction of fasting plasma glucose after 90 days.